Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients

H. Y. Meltzer, S. M. Stahl

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Blood platelet monoamine oxidase (MAO) activity was measured in 12 chronic schizophrenic (CS) and 10 acute schizophrenic (AS) patients, and in 15 normal controls using 4 substrates. Platelet MAO activity of the CS patients was significantly lower than that of the controls with all 4 substrates. With the AS patients, platelet MAO activity was lower than that of the controls only with meta iodobenzylamine (MIB) or tyramine as substrates. Octopamine tended to be the best substrate for both patient groups and the lowest (together with tryptamine) for the control groups. MIB was the best substrate for the control group but the least active for the patients. Tyramine was the best substrate in distinguishing the schizophrenic patients and controls. Variations in the affinities of MAO for the multiple substrates suggest that the platelet MAO of AS and CS patients, and controls may contain different forms of MAO. Caution is urged in extrapolating the results from platelets to brain MAO and possible abnormalities of bioamine metabolism in schizophrenia.

Original languageEnglish (US)
Pages (from-to)419-431
Number of pages13
JournalRES.COMMUN.CHEM.PATH.PHARMACOL.
Volume7
Issue number2
StatePublished - Jan 1 1974

Fingerprint

Monoamine Oxidase
Platelets
Blood Platelets
Substrates
Octopamine
Control Groups
Tyramine
Metabolism
Brain
Schizophrenia
Blood

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Toxicology
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{2f49f80248b4456e9cddb592818b575f,
title = "Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients",
abstract = "Blood platelet monoamine oxidase (MAO) activity was measured in 12 chronic schizophrenic (CS) and 10 acute schizophrenic (AS) patients, and in 15 normal controls using 4 substrates. Platelet MAO activity of the CS patients was significantly lower than that of the controls with all 4 substrates. With the AS patients, platelet MAO activity was lower than that of the controls only with meta iodobenzylamine (MIB) or tyramine as substrates. Octopamine tended to be the best substrate for both patient groups and the lowest (together with tryptamine) for the control groups. MIB was the best substrate for the control group but the least active for the patients. Tyramine was the best substrate in distinguishing the schizophrenic patients and controls. Variations in the affinities of MAO for the multiple substrates suggest that the platelet MAO of AS and CS patients, and controls may contain different forms of MAO. Caution is urged in extrapolating the results from platelets to brain MAO and possible abnormalities of bioamine metabolism in schizophrenia.",
author = "Meltzer, {H. Y.} and Stahl, {S. M.}",
year = "1974",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "419--431",
journal = "Research Communications in Chemical Pathology and Pharmacology",
issn = "0034-5164",
publisher = "PJD Publications Ltd",
number = "2",

}

Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. / Meltzer, H. Y.; Stahl, S. M.

In: RES.COMMUN.CHEM.PATH.PHARMACOL., Vol. 7, No. 2, 01.01.1974, p. 419-431.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients

AU - Meltzer, H. Y.

AU - Stahl, S. M.

PY - 1974/1/1

Y1 - 1974/1/1

N2 - Blood platelet monoamine oxidase (MAO) activity was measured in 12 chronic schizophrenic (CS) and 10 acute schizophrenic (AS) patients, and in 15 normal controls using 4 substrates. Platelet MAO activity of the CS patients was significantly lower than that of the controls with all 4 substrates. With the AS patients, platelet MAO activity was lower than that of the controls only with meta iodobenzylamine (MIB) or tyramine as substrates. Octopamine tended to be the best substrate for both patient groups and the lowest (together with tryptamine) for the control groups. MIB was the best substrate for the control group but the least active for the patients. Tyramine was the best substrate in distinguishing the schizophrenic patients and controls. Variations in the affinities of MAO for the multiple substrates suggest that the platelet MAO of AS and CS patients, and controls may contain different forms of MAO. Caution is urged in extrapolating the results from platelets to brain MAO and possible abnormalities of bioamine metabolism in schizophrenia.

AB - Blood platelet monoamine oxidase (MAO) activity was measured in 12 chronic schizophrenic (CS) and 10 acute schizophrenic (AS) patients, and in 15 normal controls using 4 substrates. Platelet MAO activity of the CS patients was significantly lower than that of the controls with all 4 substrates. With the AS patients, platelet MAO activity was lower than that of the controls only with meta iodobenzylamine (MIB) or tyramine as substrates. Octopamine tended to be the best substrate for both patient groups and the lowest (together with tryptamine) for the control groups. MIB was the best substrate for the control group but the least active for the patients. Tyramine was the best substrate in distinguishing the schizophrenic patients and controls. Variations in the affinities of MAO for the multiple substrates suggest that the platelet MAO of AS and CS patients, and controls may contain different forms of MAO. Caution is urged in extrapolating the results from platelets to brain MAO and possible abnormalities of bioamine metabolism in schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0015993861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015993861&partnerID=8YFLogxK

M3 - Article

C2 - 4594367

AN - SCOPUS:0015993861

VL - 7

SP - 419

EP - 431

JO - Research Communications in Chemical Pathology and Pharmacology

JF - Research Communications in Chemical Pathology and Pharmacology

SN - 0034-5164

IS - 2

ER -